Vincerx Pharma, Inc.
VINCDelisted Apr 28, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001796129
Vincerx Pharma, Inc. was delisted on Apr 28, 2025; its insiders filed their last Form 4 on Aug 14, 2024; 14 institutions reported holding it in 13F filings for Q1 2025, worth $116.8K in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in Vincerx Pharma, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
VINC is no longer listed, and 13F filings after Q1 2025 list far fewer holders. See Q1 2025
- Institutional holders
- 1
- −13 vs. Q1 2025
- Shares held
- 50
- −220.6K (−100.0%) vs. Q1 2025
- Total value
- $2
- −$116.8K (−100.0%) vs. Q1 2025
- New holders
- 1
- 0 more added
- Sold out
- 14
- 0 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VINC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $2 |
| Q1 2025 | 14 | $116.8K |
| Q4 2024 | 21 | $1.26M |
| Q3 2024 | 26 | $7.89M |
| Q2 2024 | 28 | $8.66M |
| Q1 2024 | 38 | $42.7M |
| Q4 2023 | 33 | $11.6M |
| Q3 2023 | 35 | $10.8M |
| Q2 2023 | 34 | $15.7M |
| Q1 2023 | 35 | $13.3M |
| Q4 2022 | 34 | $13.0M |
| Q3 2022 | 43 | $20.0M |
| Q2 2022 | 49 | $18.4M |
| Q1 2022 | 65 | $65.1M |
| Q4 2021 | 55 | $156.8M |
| Q3 2021 | 55 | $248.9M |
| Q2 2021 | 56 | $157.3M |
| Q1 2021 | 36 | $171.0M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Vincerx Pharma, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank & Trust Co | 50 | $2 | 0.00% | +50 | New |
| Sage Rhino Capital LLC | 0 | $0 | 0.00% | −85,170−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −42,777−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −31,567−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −19,285−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −14,317−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,053−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −10,798−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,997−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −2,352−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −142−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −102−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1−100.0% | Sold out |